ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2502

Self-Reported Sleep Disorders Among Individuals with Systemic Lupus Erythematosus

Patti Katz1, Maria Dall'Era2, Jinoos Yazdany3 and Kaleb Michaud4, 1University of California San Francisco, San Rafael, CA, 2University of California San Francisco, San Francisco, CA, 3University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, 4University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2023

Keywords: Aging, sleep, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: Interprofessional OA & Lupus

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Research in the general population has linked sleep disorders to poor outcomes such as lower pain thresholds, fatigue, cognitive impairment, depression, and cardiovascular disease – important health outcomes relevant to lupus, as well as higher levels of systemic inflammation, which may influence SLE disease activity and symptoms. SLE-specific studies have linked self-reported sleep problems with greater disease activity and symptoms and even risk of lupus onset. Some sleep disorders are more common among older individuals. We examine the prevalence of self-reported sleep disorders in two SLE cohorts, one with greater representation from older adults with SLE.

Methods: Data are from participants with physician-confirmed SLE in the California Lupus Epidemiology Study (CLUES) and the FORWARD Databank. In one data collection period in each study, we examined two sleep disorders: obstructive sleep apnea (OSA) using the validated STOP-Bang questionnaire and self-reported OSA diagnosis, and restless legs syndrome (RLS) using validated self-reported questions and self-reported RLS diagnosis. We examined the prevalence of OSA and RLS and the overlap between the two in each cohort. Unadjusted analyses identified significant associations between OSA and RLS and sociodemographic (age, sex, income, education), general health (smoking, obesity, comorbidities [Rheumatic Disease Comorbidity Index, RDCI), and SLE-related (SLE duration, self-reported disease activity [Systemic Lupus Activity Questionnaire, SLAQ], and damage [Brief Index of Lupus Damage, BILD], 0-10 pain rating, glucocorticoid use, use of immunosuppressive medications) characteristics. Multivariable analyses to identify independent associations of sleep disorders included all variables significant at p≤0.10 in unadjusted analyses.

Results: Mean age was 50 ± 14 years in CLUES and 61 ± 12 years in FORWARD (Table 1). Prevalence of each sleep disorder was higher in the older FORWARD cohort and considerably higher in both cohorts than in the general population (Table 1). In CLUES and FORWARD, 36.7% and 53.8% of participants, respectively, had at least one sleep disorder. In multivariable analyses, SLAQ, pain, and a higher number of comorbid conditions were the most consistent factors associated with sleep disorders (Tables 2 and 3).Obesity (BMI ≥30 kg/m2) was also associated with OSA.

Conclusion: High proportions of individuals in both of these SLE cohort had sleep disorders; prevalence was greater in the older cohort. Factors associated with sleep disorders – comorbid conditions, disease activity, and pain – were similar in the two cohorts. Given the association of sleep disorders with poor health outcomes, increased awareness of and screening for sleep disorders among SLE patients may be beneficial, particularly among older adults who may be more likely to have sleep disorders and be more sensitive to the negative impacts of sleep disorders.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: P. Katz: None; M. Dall'Era: Annexon Biosciences, 2, 5, AstraZeneca, 2, Aurinia, 2, Biogen, 2, GlaxoSmithKlein, 2, 5, Pfizer, 2; J. Yazdany: AstraZeneca, 2, 5, Aurinia, 5, Gilead, 5, Pfizer, 2; K. Michaud: None.

To cite this abstract in AMA style:

Katz P, Dall'Era M, Yazdany J, Michaud K. Self-Reported Sleep Disorders Among Individuals with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/self-reported-sleep-disorders-among-individuals-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/self-reported-sleep-disorders-among-individuals-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology